<DOC>
	<DOCNO>NCT01439711</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer block use estrogen tumor cell lower amount estrogen body make . PURPOSE : This phase II trial study well letrozole work treat woman ductal carcinoma situ .</brief_summary>
	<brief_title>Letrozole Treating Postmenopausal Women With Ductal Carcinoma Situ</brief_title>
	<detailed_description>Treatment letrozole begin within 21 day registration , notification receive UCSF Breast MRI Research Laboratory baseline MRI acceptable . Protocol therapy consist 6 month letrozole , administer orally dose 2.5 mg/day . Patients MRI disease evaluation month 3 6 . All patient continue take study drug day prior surgery , whether month 3 month 6 may stop experience unacceptable toxicity . It expect decision regard adjuvant treatment ( eg , radiation hormonal therapy ) make individually base best practice guideline , use inform shared decision make patient provider . The primary secondary objective provide . Primary objective : 1 . To estimate mean change MRI tumor volume pretreatment completion preoperative endocrine therapy estrogen receptor-positive ( ER+ ) ductal carcinoma situ ( DCIS ) , well determine whether 3-month change volume correlate 6-month change . Secondary objective : 1 . To assess radiographic-pathologic correlation MRI finding histopathology , include prevalence occult invasive cancer patient undergo neoadjuvant endocrine therapy DCIS . 2 . To compare change MRI maximum lesion diameter mammographic extent baseline follow treatment . These two additional radiographic parameter may also biological response therapy . 3 . To determine practice pattern adjuvant hormonal radiation therapy patient complete neoadjuvant letrozole therapy DCIS . 4 . To determine whether Ki67 reduce neoadjuvant letrozole treatment DCIS , compare reduction proliferation radiographic responder non-responders . 5 . To identify baseline IHC expression biomarkers predictive response treatment , response determine extent Ki67 reduction . Subsets show great reduction Ki67 would likely candidate non-operative treatment future study . 6 . To examine whether germline polymorphism associate clinical endpoint , include treatment-related toxicity efficacy outcome , expression biomarkers serum tumor . 7 . To assess quality-of-life musculoskeletal symptom associate neoadjuvant letrozole ER positive DCIS . Patients follow 6 month post-surgery .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Eligibility Criteria : 1 . Histologic documentation : Pathologic confirmation ductal carcinoma situ ( DCIS ) female breast without invasive cancer , diagnosis render core biopsy , complete within 60 day registration . Patients diagnose DCIS basis surgical biopsy eligible study . 1 . Patients microinvasion diagnostic core biopsy , define tumor ≤ 1 mm great dimension , allow participate . 2 . All patient must clip place , either time diagnostic biopsy time baseline MRI prior start treatment . 2 . Tissue sample : Patient diagnostic tissue available correlative study . 3 . Clinical stage : Tis T1mi N0 , M0 4 . Hormone receptor status : DCIS must express estrogen and/or progesterone receptor , determine immunohistochemical method diagnostic pathology sample , accord local institution 's standard protocol . Greater equal 1 % cell consider positive . 5 . Menopausal status : Patients must postmenopausal define : 1 . Age ≥ 55 year one year amenorrhea 2 . Age &lt; 55 year one year amenorrhea , estradiol assay &lt; 20pg/ml 3 . Surgical menopause bilateral oophorectomy ( least 28 day must elapse surgery time study registration ) The use GnRH analog achieve post menopausal status allow . 6 . Prior treatment : 1 . No prior surgical excision index breast current DCIS diagnosis DCIS 2 . Any exogenous hormone therapy must complete 4 week prior registration 3 . Any patient history tamoxifen raloxifene use within two year current DCIS diagnosis eligible 4 . No prior neoadjuvant/adjuvant therapy current DCIS diagnosis 7 . Contraindication MRI : No contraindication breast MRI 8 . Measurable disease : Mammographic extent calcification must accurately measurable least one dimension lesion ≥ 1 cm ≤ 7 cm 1 . DCIS must visible MRI base central review . 2 . Patients palpable DCIS adenopathy eligible participate . 3 . Patients multifocal bilateral disease eligible . 9 . History osteoporosis : Women diagnose osteoporosis may participate trial provide receive appropriate therapy decline therapy . 10 . Age : Patients ≥ 18 year age 11 . Performance Status : ECOG performance status 0 1 12 . Pregnancy/nursing status : Not pregnant nursing 13 . Required Initial Laboratory Values : 1 . ANC ≥ 1,000/μL 2 . Platelet count ≥ 100,000/μL 3 . Serum creatinine ≤ 1.7 mg/dL 4 . Bilirubin ≤ 2.0 mg/dL 5 . AST/ALT ≤ 2.5 time upper limit normal 6 . Serum estradiol level assay &lt; 20 pg/mL *Required patient &lt; 55 year age one year amenorrhea</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
</DOC>